WO1994015959A1

WO1994015959A1 - New peptides

Info

Publication number: WO1994015959A1
Application number: PCT/SE1993/001090
Authority: WO
Inventors: Peter Schiller
Original assignee: Astra Aktiebolag
Priority date: 1993-01-05
Filing date: 1993-12-20
Publication date: 1994-07-21
Also published as: NZ259597A; PL309778A1; IL108169A0; FI953302A0; LV10962A; KR960700269A; AU5844894A; AP9400605A0; CN1096515A; SK83995A3; CZ171195A3; CA2152380A1; YU394A; ZA9455B; EE9400326A; NO952650L; LV10962B; HUT72597A; AP508A; SI9400005A

Abstract

Compounds of formula (I) as well as methods for their preparation, their pharmaceutical preparations and their use. The compounds of formula (I) are useful in therapy, especially as analgesics and as immunosuppressive agents. R3, R4, R5, R6 are all H or R4 and R5 are both H and R3 and R6 are both lower alkyl groups or R3, R5, R6 are all H and R4 is F, Cl, Br, OH, NH2 or NO2; R7 is C = O or CH2; R8 is H or a lower alkyl group; R9 is (II), wherein m is 0-2 or (III) or (IV) or (V) or (VI) or (VII) or (VIII) wherein R10 is H, F, Cl, Br or I and m is 0-2; R11 is OH, NH2 or (IX) wherein R12 is H, NO2, F, Cl, Br or I, m is 0-2, R13 is COOH, CONH2, CH2OH, or any additional amino acid or peptide segment, or R11 is (X) wherein R14 is COOH, CONH2, CH2OH, or any additional amino acid or peptide segment; with the exceptions of the compounds wherein R1, R2, R3, R4, R5, R6 and R8 are all H, R7 is C = O and R9 is (XI) and R11 is Phe-OH, Phe-NH2, OH or NH2.

Description

New peptides

The field of the Invention

This invention is related to a new class of opioid peptide analogs that are δ opioid receptor antagonists as well as to their synthesis and their use as analgesic and immunosuppressive compounds.

Background

A known nonpeptide δ opioid antagonist is naltrindole, which is described by P.S Portoghese, et al J. Med. Chem. 31, 281-282 (1988). Naltrindole has similar δ- antagonist potency as the compounds according to this invention but is much less δ selective. Furthermore, naltrindole has also quite high μ opioid receptor affinity (K_i ^μ=12nM) in the receptor binding assay and potent antagonist properties

(K_e=29nM) in the guinea pig ileum (GPI) assay, cf P.S. Portoghese, J. Med. Chem. 34, 1757-1762 (1991).

Another known δ-antagonist is the enkephalin analog N,N-diallyl-Tyr-Aib-Aib-Phe- Leu-OH (ICI 174864) described by R. Cotton, et al. in Eur. J. Pharmacol. 97, 331- 332 (1984). In comparison with the δ antagonists described in this patent application, ICI 174864 is much less δ-selective (10-300 times less) and has much lower antagonist potency in the MVD assay (40-1000 times less potent). Prior art

Tetrapeptides, which are potent δ antagonists have recently been disclosed by P.W Schiller, et al in FASEB J. 6. (No 4), A 1575 (1992), at the International Narcotics Research Conference (INRC) Meeting, Keystone, CO, June 24-29, (1992) and at the 2nd Japan Symposium on Peptide Chemistry, Shizuoka, Japan, Nov. 9-13, 1992.

The Invention

It has now unexpectedly been found that the compounds of the following formula I have

- extraordinary selectivity for the δ receptor

- high potency as δ antagonists

- total lack of μ antagonist properties

- mixed μ agonist/δ antagonist properties in some cases (ΗPP analogs with a C- terminal carboxamide group)

The compounds according to the present invention have the formula I

wherein R₁ is H, CH₃(CH₂)_n- wherein n = 0-12-, CH₂-CH₂ -

CH₂-CH=CH₂ or arginine;

R₂ is H, CH₃(CH₂)_n- wherein n = 0-12-, CH₂, CH₂

CH₂-CH=CH₂;

R₃, R₄, R₅, R₆ are all H or

R₄ and R₅ are both H and R₃ and R₆ are both lower alkyl groups or R₃, R₅, R₆ are all H and R₄ is F, Cl, Br, OH, NH₂ or NO₂;

R₇ is C=O or CH₂; R₈ is H or a lower alkyl group

R₉ is

wherein m is 0-2 or or

or or

or

wherein

R₁₀ is H, F, Cl, Br or 1 and m is 0-2;

R₁₁ is OH, NH₂ or

wherein R₁₂ is H, NO₂, F, Cl, Br or I, m is 0-2, R₁₃ is COOH, CONH₂, CH₂OH, or any additional amino acid or peptide segment, or

R_{1 1} is

wherein

R₁₄ is COOH, CONH₂, CH₂OH, or any additional amino acid or peptide segment; with the exceptions of the compounds wherein R₁, R₂, R₃, R₄, R₅, R₆ and R₈ are all H, R₇ is C = O and

R₉ is

and R_{1 1} is Phe-OH, Phe-NH₂, OH or NH₂. A lower alkyl group has according to this specification 1-6 carbon atoms.

Especially preferred compounds according to the invention are those wherein R₇ is CH₂ (as part of a reduced peptide bond). A reduced peptide bond gives the compound higher δ antagonist potency, increased δ-selectivity, better stability in organic solvents and resistance to enzymatic degradation.

Further preferred compounds according to the invention are those, wherein R₄ and R₅ are H and R₃ and R₆ are both methyl groups. Synthesis

Most Boc-amino acid derivatives used in the peptide syntheses were commercially available. 2,6-dimethyl-tyrosine (Dmt) was prepared as described by J.H Dygos et al. Synthesis, No 8 (August) pp. 741-743 (1992) and 2-aminotetralin 2-carboxylic acid as described by P.W. Schiller et al in J. Med. Chem 34, 3125-3132 (1991).

All peptides were prepared by solid-phase techniques. The usual polystyrene/- divinylbenzene resin was used for the solid-phase synthesis of peptides with a free C-terminal carboxyl group, whereas peptide amides were synthesized by using the p-methylbenzhydrylamine resin. Boc protection of the amino group was employed in the preparation of all peptides. The syntheses were performed according to protocols that have been extensively used in the inventor's laboratory (P.W Schiller et al, Biochemisty 16, 1831-1832 (1977)). Couplings were performed in CH₂Cl₂ or DMF, using dicyclohexylcarbodiimide/l-hydroxybenzotriazole (DCC/HOBt) as coupling agents. Completeness of coupling was carefully examined after each coupling step by means of the ninhydrin color test. The fully assembled peptide chain was cleaved from the resin and completely deprotected by treatment with liquid HF at 0°C and in the presence of anisole as scavenger (60-90 min). Analogs containing the CH₂NH peptide bond isostere were prepared by solid-phase synthesis according to a procedure developed by Sasaki and Coy (Y. Sasaki & D.H. Coy, Peptides 8, 119-121 (1987)). With this method the CH₂NH peptide bond can be directly introduced by the reductive alkylation reaction between a Boc- amino acid aldehyde and an amino group on the resin-bound peptide employing sodium cyanoborohydride in acidified DMF. No significant racemization was observed with this method. Boc-Tic aldehyde was synthesized via the

corresponding Boc-Tic N-methoxy-N-methylamide by the reportedly racemization- free LiAlH₄ reduction method (J.A Fehrentz & B. Castro, Synthesis, 676-678 (1983)). Peptides containing reduced peptide bonds were cleaved from the resin and deprotected by treatment with HF/anisole as described above.

Crude products obtained from solid-phase peptide synthesis required extensive purification by various chromatographic techniques or by other methods. Following HF cleavage and extraction of the resin, gel filtration on Sephadex (G-15 or G-25) was routinely performed. Various subsequent purification steps included partition chromatography on Sephadex G-25 (using various butanol-acetic acid-pyridine- water two phase systems), ion exchange chromatography (DEAE-Sephadex, SP- Sephadex and CM-cellulose) and reversed-phase chromatography on an

octadecasilyl-silica column using linear gradients of methanol in 1% trifluoroacetic acid (low pressure). If necessary, final purification to homogeneity was performed by semi-preparative HPLC. Semi-preparative μ-Bondapak C-18 columns (Waters; 0.7x25 cm), which, depending on the separation problem, permitted purification of 2-20 mg peptide material per run were used. Several highly sensitive and efficient analytical methods were used to demonstrate homogeneity of the prepared peptides and to verify their structures. Thin layer chromatography in at least two different solvent systems was used to establish purity. Furthermore, analytical HPLC in two or three different solvent systems was routinely used in the laboratory as a highly sensitive purity test. Verification of peptide structures was mainly based on amino acid analysis and fast atom bombardment-mass spectrometry (FAB-MS). For amino acid analyses, peptides were hydrolyzed in 6N HCl containing a small amount of phenol for 24 h at 110°C in deaerated tubes (in some case hydrolyses lasting for 12 and 48 h were also performed to take into account amino acid degradation).

Hydrolysates were analyzed on a Beckman Model 121 C amino acid analyzer equipped with a system AA computing integrator. FAB mass spectrometry was used to establish the correct molecular weights of the peptides.

EXAMPLES OF PARTICULAR ANALOGS EXAMPLE 1

H-Tyr-Tic-Hfe-Phe-OH

Boc-Phe-O-resin (1g, 0.61 mmol Boc-Phe/g resin; Peninsula, Belmont, CA) was washed with reagents in the following sequence: CH₂CI₂ (3x 1 min), 50% (v/v) TFA in CH₂Cl₂ (30 min), CH₂Cl₂ (5x1 min), 10% (v/v) DIEA in CH₂Cl₂ (2x5 min), CH₂Cl₂ (5x1 min). Boc-Hfe-OH (425 mg, 1.52 mmol) was then coupled using HOBt (205 mg, 1.52 mmol) and DCC (313 mg, 1.52 mmol) in CH₂Cl₂/DMF (3:1, v/v) for 17h. The resin was then washed with CH₂Cl₂ (3x1 min), EtOH (1 min), CH₂CI₂ (3x1 min). This sequence of washes and reactions was repeated for the addition of each of the residues with the following modifications.

After coupling of Boc-Tic-OH the resin was washed with CH₂Cl₂/DMF (3: 1, v/v) (3x) and a recoupling step using the same amounts of Boc-Tic-OH, HOBt and DCC in CH₂CI₂/DMF (3:1, v/v) was performed for another 17h. The same recoupling step was also carried out to couple Boc-Tyr(Boc)-OH.

After final deprotection with 50% (v/v) TFA in CH₂Cl₂ (30 min), the resin was washed with CH₂Cl₂ (3x1 min) and EtOH (3x1 min) and was dried in a desiccator. The dry resin was treated with 20 ml of HF plus 1 ml of anisole first for 90 min at 0°C and then for 15 min at room temperature. After evaporation of the HF, the resin was extracted three times with Et₂O and, subsequently three times with 7% AcOH. The crude peptide was then obtained in solid form through lyophilization of the combined acetic acid extracts.

The peptide was purified by gel filtration on a Sephadex-G-25 column in 0.5 N AcOH followed by reversed-phase chromatography on an octadecasilyl silica column with a linear gradient of 0-80% MeOH in 1% TFA. After solvent evaporation the pure peptide was dissolved in cone. AcOH and was obtained in solid form through lyophilization. Yield: 45 mg

FAB-MS:MH⁺ = 648

TLC (silica) Rf 0.75 n-BuOH/AcOH/H₂O (4/1/5, organic phase)

Rf 0.70 n-BuOH/Pyridine/AcOH/H₂O (15/10/3/12) Amino acid analysis: Tyr 0.96, Hfe 1.03, Phe 1.00

EXAMPLE 2

H-Tyr-TicΨ[CH₂-NH]Phe-Phe-OH

The synthesis of this peptide was performed as in the case of EXAMPLE 1 using the same resin, except that the introduction of a reduced peptide bond between the

Tic² and Phe³ residue required a reductive alkylation reaction between Boc-Tic aldehyde and the amino group of the resin-bound H-Phe-Phe dipeptide.

Preparation of N-t-butoxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-3-aldehyde (Boc-Tic aldehyde) via N-t-butoxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-3-N- methoxy, N-methylamide. BOP (benzotriazol-1-yl-oxytris(dimethylamino]phosphonium hexafluorophosphate) (3.48 g, 10 mmol) was added to a stirred solution of Boc-Tic-OH (2.8 g, 10 mmol) and triethylamine (1.33 ml, 10 mmol) in CH₂Cl₂. After five minutes, N- dimethylhydroxylamine hydrochloride (1.2 g, 12 mmol) and triethylamine (1.68 ml, 12 mmol) were added to the solution. The reaction was carried out for 17h.

Subsequently, the reaction mixture was diluted with dichloromethane and washed with 3N HCl, a saturated aqueous solution of NaHCO₃ and a saturated aqueous solution of NaCl. The organic solution was dried over MgSO₄ prior to evaporation of the solvent The resulting crude product of N-t-butoxycarbonyl-L-1,2,3,4- tetrahydroisoquinoline-3-N-methoxy, N-methylamide was purified by

chromatography on a silica gel column in EtOAc/hexane(1:2, v/v).

Yield: 2.1 g (65%), oil

TLC (silica) Rf 0.57 EtOAc/hexane (1/1)

Rf 0.30 EtOAc/hexane (1/2)

NMR (CDCl₃) δ 1.45 (9H, t-butyl), 3.00 (2H,H-4), 3.18 (3H, NCH₃),

3.8(3H, OCH₃), 4.42-4.90(3H, 2H-1 and 1H-3), 7.17(4H, ar)

To a stirred solution of N-t-butoxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-3-N- methoxy, N-methyamide (1.2 g, 4mmol) in 30 ml ether 190 mg (5 mmol) of lithium aluminium hydride were added. The reduction reaction was carried out for lh and the reaction mixture was then hydrolyzed with a solution of KHSO₄ (954 mg, 7 mmol) in water (20 ml). Subsequently, the aqueous phase was separated and extracted with three 50 ml portions of ether. The four organic phases were combined, washed with 3 N HCl, a saturated aqueous solution of NaHCO₃ and a saturated aqueous solution of NaCl, and finally dried over MgSO₄. After solvent evaporation the aldehyde was obtained in pure form as an oil.

Yield: 635 mg (60%), oil

TLC (silica) Rf 0.84 EtOAc/hexane (1/1)

Rf 0.57 EtOAc/hexane (1/2)

NMR(CDCl₃) δ 1.5 (9H, t-butyl), 3.0-3.27 (2H, H-4), 4.4-4.8

(3H, 1H-3 and 2H-1), 7.0 - 7.2 (4H, ar), 9,43 (1H, CHO) Reductive alkylation reaction between Boc-Tic aldehyde and the H-Phe-Phe-O resin

The resin was washed with DMF (2x1 min) and then Boc-Tic aldehyde (392 mg, 1.52 mmol) in DMF containing 1% AcOH was added to the resin. Sodium cyanoborohydride (115 mg, 1.83 mmol) was then added portionwise over a period of 40 min and the reaction was allowed to continue for 3h.

After coupling of the N-terminal tyrosine residue and deprotection the peptide was cleaved from the resin, purified and lyophilized as described in EXAMPLE 1. Yield: 180 mg

FAB-MS: MH⁺ = 633

TLC (silica) Rf 0.73 n-BuOH/AcOH/H₂O (4/1/5, organic phase)

Rf 0.69 n-BuOH/pyridine/AcOH/H₂O (15/10/3/12)

Amino acid analysis: Tyr 0.95, Phe 1.00

The following compounds according to the invention have been synthesized and tested as δ antagonists. Pharmacological testing in vitro of δ opioid antagonists a) Biosassys based on inhibition of electrically evoked contractions of the mouse vas deferens (MVD) and of the guinea pig ileum (GPI). In the GPI assay the opioid effect is primarily mediated by μ opioid receptors, whereas in the MVD assay the inhibition of the contractions is mostly due to interaction with δ opioid receptors. Antagonist potencies in these assays are expressed as so-called K_e-values (H.W. Kosterlitz & A.J. Watt, Br. J. Pharmacol. 33, 266-276 (1968)). Agonist potencies are expressed as IC50 values (concentration of the agonist that produces 50% inhibition of the electrically induced contractions).

Bioassays Using Isolated Organ Preparations

The GPI and MVD bioassays were carried out as reported in P.W. Schiller et al., Biochem. Biophys. Res. Commun 85, 1332-1338 (1978) and J. Di Maio et al., J. Med. Chem. 25, 1432-1438 (1982). A log dose-response curve was determind with [Leu ] enkephalin as standard for each ileum and vas preparation, and IC50 values of the compounds being tested were normalized according to A. A Waterfield et al., Eur. J. Pharmacol. 58, 11-18 (1979). K_e values for the TIPP-related antagonists were determind from the ratio of IC50 values (DR) obtained in the presence and absence of a fixed antagonist concentration (a) (K_e= a/(DR-l)) H.W. Kosterlitz & A.J. Watt, Br. J. Pharmacol. 33, 266-276 (1968). These determinations were made with the MVD assay, using three different δ-selective agonists ([Leu ] enkephalin,

DPDPE and [D-Ala²]deltorphin I].

In the following Table 1 the results are given. Table 1

K_e-values of TTP(P) related peptides in the MVD assay (Antagonist potencies

against the δ agonists [Leu5] enkephalin, [D-Pen², D-Pen⁵]enkephalin (DPDPE) and [D-Ala²]deltorphin I)

(Prior known compounds are marked (P)

aValues are means of 3-8 determinations 1 SEM

bH-Tyr-Tic-Phe-Phe-NH₂, H-Dmt-Tic-Phe-Phe-NH₂ and H-Dmt-Ticψ[CH₂-

NH]Phe-Phe-NH ₂ are mixed μ agonist/δ antagonists showing IC50s of 1700±220 nM, 18.2±1.8 nM and 7.71±0.32 nM, respectively, in the guinea pig ileum (GPI) assay.

Conclusion

μ Antagonist or μ Agonist behavior of TIPP-related δ antagonists

- All compounds show no μ antagonist activity in the GPI assay at concentrations as high as 10 μM.

- TIPP-related peptides with a free C-terminal carboxyl group have very weak μ agonist potency in the GPI assay (IC50 > 10μM). On the other hand, TTPP-derived peptides with a C-terminal carboxamide function show full μ agonist potency in the GPI assay (e.g. H-Dmt-Tic-Phe-Phe-NH₂) has an IC50 of 18.2±1.8 nM in the GPI assay.

Opioid receptor binding assays μ and δ opioid receptor binding constants (K_i ^μ, K_i ^δ ) of the compounds were determined by displacement of relatively selective μ and δ radioligands from binding sites in rat brain membrane preparations (calculated from the measured IC50 values on the basis of the equation by Cheng & Prusoff (Y.C. Cheng and W.H. Prusoff (Biochem. Pharmacol. 22, 3099-3102 (1973)).

In the foUwing Table 2 the results of opioid receptor binding assays are given. The ratio K_i ^μ / K_i ^δ is a quantitative measure of the δ-selectivity.

The higher the ratio the better the δ-selectivity. Opioid receptor binding studies

The μ-, δ- and κ-opioid receptor affinities of all new analogs were determined in binding assays based on displacement of μ-, δ-and κ-selective radioligands from rat brain membrane binding sites. In the case of κ-ligands guinea pig brain homogenates were used, since the relative proportion of κ-binding sites is higher in guinea pig brain than in rat brain. The experimental procedure being used in our laboratory represents a modified version of the binding assay described by

Pasternak et al. (Mol. Pharmacol. 11, 340-351, (1975)). Male Sprague-Dawley rats (300-350 g) from the Canadian Breeding Laboratories were decapitated and after removal of the cerebellum the brains were homogenized in 30 volumes of ice-cold standard buffer (50 mM Tris-HCl, pH 7.7). After centrifugation at 30,000 x g for 30 min at 4°C the membranes were reconstituted in the original volume of standard buffer and incubated for 30 min at 37° C (to realease bound endogenous ligands). Subsequent centrifugation and resuspension of the pellet in the initial volume of fresh standard buffer yielded the final membrane suspension. Aliquots (2 ml) of the membrane preparations were incubated for 1-2 h at 25°C with 1 ml standard buffer containing the peptide to be tested and one of the following radioligands at the final concentration indicated: [³H]DAMGO, μ-selective, 0.7 nM; [³H]DSLET, [³H]DPDPE, or [³H]TIPP, δ-selective, 1.0 nM; and [³H]U69,563, κ-selective, 0.5 nM. The incubation was terminated by filtration through Whatman GF/B filters under vacuum at 4°C. Following two washings with 5 ml portions of ice-cold standard buffer the filters were transferred to scintillation vials and treated with 1 ml Protosol (New England Nuclear) for 30 min prior to the addition of 0.5 ml acetic acid and 10 ml Aquasol (New England Nuclear). After shaking for 30 min the vials were counted at an efficiency of 40-45%. All experiments were performed in duplicates and repeated at least three times. Specific binding of each of the three radioligands was defined by performing incubations in the presence of cold DAMGO, DSLET and U69.563, respectively, at a concentration of 1 micromolar. Values of half-maximal inhibition (IC50) of specific binding were obtained graphically from semiiogarithmic plots. From the measured IC50-values, binding inhibition constants (K_i)were then calculated based on Cheng and Prusoff's equation (Biochem, Pharmcol. 22, 3099-3102 (1973)). Ratios of the K_i-values in the μ-, δ- and κ-representative binding assays are a measure of the receptor selectively of the compound under investigation (e.g. K_i ^μ/K_i ^δ indicates the selectivity for δ-receptors versus μ-receptors). None of the compounds according to the claimed invention had significant affinity for κ-receptors.

Table 2

-end of table 2- aValues are means of 3 determinations ± SEM Potential use

The pure δ antagonists may be used in combination with analgesics of the μ agonist type (e.g. morphine) to prevent the development of tolerance and dependence, as suggested by the results of E.E. Abdelhamid et al., J. Parmacol. Exp. Ther. 258, 299-303 (1991). The latter study also suggested that compounds with mixed μ agonist/δ antagonist properties may be therapeutically useful as analgesics that do not produce tolerance and dependence. The TIPP-related peptides with a C-terminal carboxamide group described in this patent are the first mixed μ agonist/δ antagonists known.

The δ antagonists described in the patent may also be therapeutically useful as immunosuppressive agents. Immunosuppressive effects of the less δ-selective and less "pure" δ antagonist naltrindole have been described by K. Arakawa et al.

Transplantation Proc. 24, 696-697 (1992); Transplantation 53, 951-953 (1992).

Abbreviations

Aib= α-aminoisobutyric acid

Atc= 2-aminotetralin-2-carboxylic acid

Boc= tert-butoxycarbonyl

Cpm=cyclopropylmethyl

DAMGO= H-Tyr-D-Ala-Gly-Phe(N^αMe)-Gly-ol

DCC= dicyclohexylcarbodiimide

DEEA= diisopropylethylamine

Dmt= 2,6-dimethyltyrosine

DPDPE= [D-P

en², D-Pen⁵]enkephalin

DSLET= H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH

Et=ethyl

FAB-MS= fast atom bombardment mass spectrometry

GPI= guinea pig ileum

Hex= hexyl

Hfe= homophenylalanine

HOBt= 1-hydroxybenzotriazole

MVD= mouse vas deferens

1-Nal= 3-(1'-naphthyl)alanine

2-Nal= 3-(2'-naphthyl)alanine

Phe(pNO₂)=4-nitrophenylalanine

Phg= phenylglycine

Tic= 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

TIP= H-Tyr-Tic-Phe-OH

TIP-NH₂= H-Tyr-Tic-Phe-NH₂

TIP(ψ)= H-Tyr-Ticψ[CH₂-NH]Phe-OH

TIPP= H-Tyr-Tic-Phe-Phe-OH

TIPP-NH₂=H-Tyr-Tic-Phe-Phe-NH₂ TIPP(ψ)= H-Tyr-Ticψ[CH₂-NH]Phe-Phe-OH

Tyr(3-Br)= 3-bromotyrosine

Tyr(3-Cl)= 3-chlorotyrosine

Tyr(3-F)= 3-fiuorotyrosine

Tyr(N^αMe)= N^α-methyltyrosine

U69,593= (5α, 7α, 8β)-(-)-N-methyl-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8- yl]benzeneacetamide

Claims

1. A compound of the formula I

wherein

R₁ is H, CH₃(CH₂)_n- wherein n = 0-12-, CH₂-CH₂

2 CH₂-CH=CH₂ or arginine;

R₂ is H, CH₃(CH₂)_n- wherein n = 0-12-, CH₂, CH₂

CH₂-CH= CH₂; R₃, R₄, R₅, R₆ are all H or

R₄ and R₆ are both H and R₃ and R₆ are both lower alkyl groups or

R₃, R₅, R₆ are all H and R₄ is F, Cl, Br, OH, NH₂ or NO₂;

R₇ is C=O or CH₂;

R₈ is H or a lower alkyl group

R₉ is

wherein m is 0-2 or

or

or or

or

wherein

R₁₀ is H, F, Cl, Br or I and m is 0-2;

R_{1 1} is OH, NH₂ or

R_{1 1} is

wherein

R₉ is

and R_{1 1} is Phe-OH, Phe-NH₂, OH or NH₂.

2. A compound according to formula I of claim 1, wherein R₇ is a part of a reduced peptide bond.

3. A compound according to formula I of claim 1, wherein R₄ and R₅ are hydrogen and R₃ and R₆ are both methyl groups.

4. A compound according to claim 1 for use in therapy.

5. A compound according to claim 1 for use as analgesic.

6. A compound according to claim 1 for use as an immunosuppressive agent.

7. A method for preparing peptides according to claim 1 employing solid-phase synthesis.

8. The method according to claim 7, comprising an additional step of attaching the Boc-Tic-OH residue to the dipeptide resin (recoupling step) and an additional step of attaching the Boc-Tyr(Boc)-OH to the peptide resin (recoupling step).

9. The method according to any one of claims 7 - 8 wherein the suitably inert solvent is CH₂Cl₂ or a mixture of CH₂CL₂/DMF(3:1 v/v) and the coupling agents are N, N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole.

10. The method for preparing some of the peptides according to claim 1 containing a reduced peptide bond (-CH₂-NH-) between the Tic ² residue and the 3- position residue, based on a reductive alkylation reaction between Boc-Tic aldehyde and the amino group of the resin-bound peptide employing sodium cyanoborohydride in acidified DMF.

11. The method for preparing N-t-butoxycarbonyl-L-1,2,3,4-tetrahydro- isoquinoline-3-aldehyde (Boc-Tic aldehyde) for preparing peptides containing a reduced peptide bond (-CH₂-NH-) between the Tic² residue and the 3-position residue according to claim 10.

12. A pharmaceutical preparation comprising an effecive amount of a compound according to claim 1 together with one or more pharmaceutical carriers.

13. Use of a compound according to claim 1 as an active ingredient in the manufacture of an analgetic pharmaceutical preparation.

14. Use of a compound according to claim 1 as an active ingredient in the manufacture of a pharmaceutical preparation with immunosuppressive effect.

15. A method for the treatment of pain whereby an effective amount of a compound according to claim 1 is administered to a patient in the need of such treatment.

16. A method for producing immunosuppressive effects whereby an effective amount of a compound according to claim 1 is administered to a patient in the need of such treatment.